Literature DB >> 33859488

Decreased T Cell Levels in Critically Ill Coronavirus Patients: Single-Center, Prospective and Observational Study.

Jingjing Xu1, Zhiyu Liu2, Haitao Liu1, Yunpeng Luo3, Kai Kang3, Xueting Li1, Wei Yang3, Dongsheng Fei3, Changsong Wang1,3, Kaijiang Yu3.   

Abstract

BACKGROUND: Since Dec. 2019, the COVID-19 pandemic has been an outbreak. T cells play an important role in dealing with various disease-causing pathogens. However, the role of T cells played in COVID-19 patients is still unknown. Our study aimed to describe the immunologic state of the critically ill COVID-19 patients.
METHODS: A total of 63 patients with confirmed COVID-19 pneumonia were admitted to the Department of Intensive Care Unit of the First Affiliated Hospital of Harbin Medical University. The immunologic characteristics (lymphocyte apoptosis, the expression of PD-1 and HLA-DR in T cells, T cell subset levels, redistribution and the production of inflammatory factors) as well as their laboratory parameters were compared between severe group and critical group.
RESULTS: The level of T cells in peripheral blood was decreased in critical patients compared with that in severe patients, but the expression levels of PD-1 (CD4+: 24.71% VS 30.56%; CD8+: 33.05% VS 32.38%) and HLA-DR (T cells: 36.28% VS 27.44%; monocytes: 20.58% VS 23.83%) in T cells were not significantly changed, and apoptosis and necrosis were not different in lymphocytes (apoptosis: 1.04% VS 1.27%; necrosis: 0.67% VS 1.11%), granulocytes, or monocytes between those two groups.
CONCLUSION: There is severe immunosuppression in critically ill COVID-19 patients. Redistribution of T cells might be the main reason for lymphocytic decline. Decreasing the infiltration of T lymphocytes in the lung may be beneficial for the treatment of COVID-19.
© 2021 Xu et al.

Entities:  

Keywords:  COVID-19; HLA-DR; PD-1; T lymphocytes; redistribution

Year:  2021        PMID: 33859488      PMCID: PMC8044074          DOI: 10.2147/JIR.S303117

Source DB:  PubMed          Journal:  J Inflamm Res        ISSN: 1178-7031


  25 in total

1.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.

Authors:  Estelle Bettelli; Yijun Carrier; Wenda Gao; Thomas Korn; Terry B Strom; Mohamed Oukka; Howard L Weiner; Vijay K Kuchroo
Journal:  Nature       Date:  2006-04-30       Impact factor: 49.962

Review 2.  A question of self-preservation: immunopathology in influenza virus infection.

Authors:  Nicole L La Gruta; Katherine Kedzierska; John Stambas; Peter C Doherty
Journal:  Immunol Cell Biol       Date:  2007-01-09       Impact factor: 5.126

3.  Low HLA-DR expression on CD14+ monocytes of burn victims with sepsis, and the effect of carbachol in vitro.

Authors:  Hong-Ming Yang; Yan Yu; Jia-Ke Chai; Sen Hu; Zhi-Yong Sheng; Yong-Ming Yao
Journal:  Burns       Date:  2008-06-06       Impact factor: 2.744

4.  IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways.

Authors:  Liang Zhou; Ivaylo I Ivanov; Rosanne Spolski; Roy Min; Kevin Shenderov; Takeshi Egawa; David E Levy; Warren J Leonard; Dan R Littman
Journal:  Nat Immunol       Date:  2007-06-20       Impact factor: 25.606

5.  Docetaxel Down-Regulates PD-1 Expression via STAT3 in T Lymphocytes.

Authors:  Chaoyang Zhang; Feng Li; Jieyao Li; Yujie Xu; Liping Wang; Yi Zhang
Journal:  Clin Lung Cancer       Date:  2018-05-05       Impact factor: 4.785

6.  The roles of serum CXCL16 in circulating Tregs and gastrointestinal stromal tumor cells.

Authors:  Ya-Nan Xing; Jun-Yan Zhang; Hui-Mian Xu
Journal:  Onco Targets Ther       Date:  2016-06-29       Impact factor: 4.147

7.  Ebola Virus Binding to Tim-1 on T Lymphocytes Induces a Cytokine Storm.

Authors:  Patrick Younan; Mathieu Iampietro; Andrew Nishida; Palaniappan Ramanathan; Rodrigo I Santos; Mukta Dutta; Ndongala Michel Lubaki; Richard A Koup; Michael G Katze; Alexander Bukreyev
Journal:  mBio       Date:  2017-09-26       Impact factor: 7.867

8.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia.

Authors:  Qun Li; Xuhua Guan; Peng Wu; Xiaoye Wang; Lei Zhou; Yeqing Tong; Ruiqi Ren; Kathy S M Leung; Eric H Y Lau; Jessica Y Wong; Xuesen Xing; Nijuan Xiang; Yang Wu; Chao Li; Qi Chen; Dan Li; Tian Liu; Jing Zhao; Man Liu; Wenxiao Tu; Chuding Chen; Lianmei Jin; Rui Yang; Qi Wang; Suhua Zhou; Rui Wang; Hui Liu; Yinbo Luo; Yuan Liu; Ge Shao; Huan Li; Zhongfa Tao; Yang Yang; Zhiqiang Deng; Boxi Liu; Zhitao Ma; Yanping Zhang; Guoqing Shi; Tommy T Y Lam; Joseph T Wu; George F Gao; Benjamin J Cowling; Bo Yang; Gabriel M Leung; Zijian Feng
Journal:  N Engl J Med       Date:  2020-01-29       Impact factor: 176.079

9.  Return of the Coronavirus: 2019-nCoV.

Authors:  Lisa E Gralinski; Vineet D Menachery
Journal:  Viruses       Date:  2020-01-24       Impact factor: 5.048

10.  A Novel Coronavirus from Patients with Pneumonia in China, 2019.

Authors:  Na Zhu; Dingyu Zhang; Wenling Wang; Xingwang Li; Bo Yang; Jingdong Song; Xiang Zhao; Baoying Huang; Weifeng Shi; Roujian Lu; Peihua Niu; Faxian Zhan; Xuejun Ma; Dayan Wang; Wenbo Xu; Guizhen Wu; George F Gao; Wenjie Tan
Journal:  N Engl J Med       Date:  2020-01-24       Impact factor: 91.245

View more
  3 in total

Review 1.  Interleukin-6 in SARS-CoV-2 induced disease: Interactions and therapeutic applications.

Authors:  Jamal Majidpoor; Keywan Mortezaee
Journal:  Biomed Pharmacother       Date:  2021-11-12       Impact factor: 7.419

2.  Low Levels of Granulocytic Myeloid-Derived Suppressor Cells May Be a Good Marker of Survival in the Follow-Up of Patients With Severe COVID-19.

Authors:  Carlos Jiménez-Cortegana; Flora Sánchez-Jiménez; Antonio Pérez-Pérez; Nerissa Álvarez; Alberto Sousa; Luisa Cantón-Bulnes; Teresa Vilariño-García; Sandra Fuentes; Salomón Martín; Marta Jiménez; Antonio León-Justel; Luis de la Cruz-Merino; José Garnacho-Montero; Víctor Sánchez-Margalet
Journal:  Front Immunol       Date:  2022-01-28       Impact factor: 7.561

3.  Lymphocyte-C-reactive protein ratio can differentiate disease severity of COVID-19 patients and serve as an assistant screening tool for hospital and ICU admission.

Authors:  Jian-Nan Zhang; Yang Gao; Xin-Tong Wang; Na-Na Li; Xue Du; Yu-Jia Tang; Qi-Qi Lai; Peng-Fei Chen; Chuang-Shi Yue; Ji-Han Wu; Kai Kang; Ming-Yan Zhao
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.